Helicobacter Pylori and Smoking: Two Additive Risk Factors for Organic Dyspepsia

F. Halter and R. Brignoli

*GI Unit, Department of Medicine, Inselspital, University of Bern and Janssen Research Foundation, Baar, Switzerland

The hopes to distinguish between organic and functional dyspepsia on the grounds of the patient’s symptomatology have not been fulfilled due to the low specificity of the so-called sinister symptoms. There is increasing evidence accumulating that Helicobacter pylori status and other environmental factors such as smoking have a higher discriminant power. Studies performed in our laboratories testing H. pylori status on gastric biopsy samples have shown that preselection of patients according to smoking habits and H. pylori status has a higher potential in avoiding unnecessary endoscopies in primary care patients as compared to risk factors based on patient complaints. Out of a total population of 282 primary care patients, one out of 24 endoscopies revealed significant pathology such as peptic ulcer or reflux esophagitis in the non-smokers with a negative H. pylori status, but when both risk factors were positive, the percentage rose to one out of every two patients. These observation have largely been confirmed by recent studies where H. pylori status was prospectively assessed prior to endoscopy by highly specific H. pylori serology or ¹³C breath test analysis.

INTRODUCTION

Dyspepsia is defined as any pain, discomfort or nausea referable to the upper alimentary tract, which may be intermittent or continuous and has been present for at least one month [1]. Dyspepsia is a very common clinical problem accounting for two to three percent of primary care consultations and some 30 to 50 percent of cases of chronic upper abdominal complaints presented to the gastroenterologist [27]. A large proportion of these patients do not have recognizable organic disease and are commonly labelled as having functional dyspepsia. Although upper gastrointestinal endoscopy is the investigation of choice for the distinction between organic and functional dyspepsia, one must take into account that the percentage of relevant organic disease found by this invasive technique is in the range of 25 to 15 percent, whereby the lower limit refers to patients of the primary care setting [2-4].

The diseases most often diagnosed are peptic ulcer and reflux esophagitis; the possibility of underlying carcinoma exists but primarily in older patients. In adequately trained hands, ultrasonography is of special value in the search of extraintestinal organic disease, especially gallbladder pathology, which is relatively common in dyspeptic patients. Endoscopy is both unpleasant and costly, and many attempts have, therefore, been made in recent years to cut down the amount of unnecessary procedures [8]. The strategies employed are mainly based on screening for so-called clinical risk factors, also referred to as sinister symptoms, but their discriminant power is limited due to the overall low specificity of each individual factor, and it is generally recognized that no single symptom allows an unequivocal diagnosis by itself [9]. Simultaneous evaluation of specified symptoms with

*To whom all correspondence should be addressed: Dr. F. Halter, M.D., F.R.C.P., Edinb., Visiting Professor, Division of Gastroenterology, UCI Medical Center, 101 The City Drive, Building 53, Route 81, Orange, CA 92868.
linear discriminant analysis as well as stepwise logistic regression analysis, however, appears to have the potential to distinguish between functional and organic dyspepsia in approximately 70 percent of the cases [4, 5]. The low prevalence of organic disease in dyspeptic patients generally results in low positive and high negative predictive values. Consequently, the main impact of the predictive models may be to reduce the number of negative endoscopies rather than to predict a precise diagnosis [5]. In a dyspepsia study aimed at establishing the clinical characteristics and prevalences of upper gastrointestinal lesions in a large, primary-care referral, Swiss multicenter study [7], a simplified questionnaire on “risk symptoms and factors” (adapted from that proposed by Talley et al. [5]) adequately identified as “patients at risk” almost two-thirds of the patients with peptic lesions, while reducing the endoscopic workload to about one-third of the patients. Although the clinical criteria used, therefore, had some discriminant power between organic and functional dyspepsia, up to one-third of clinically relevant findings may have been missed. In recent years, particular attention has been given to age, gender and environmental factors such as smoking, drug consumption and especially *Helicobacter pylori* infection as risk factors for organic dyspepsia.

**GENETIC AND ACQUIRED RISK FACTORS**

*Role of age as risk factor*

There is circumstantial evidence available from many epidemiological studies that age above 45 is a risk factor for peptic ulcer and gastric malignancy and, to a lesser degree, also for reflux esophagitis [5]. For the latter disease, this particularly applies to the severity of the condition. Gastric malignancy is particularly rare below the age of 45 [10].

*Role of gender*

Organic dyspepsia appears to be more common in male subjects. This relates particularly to duodenal ulcer and reflux esophagitis, but not to gastric ulcer, where a higher NSAID consumption is likely responsible for the increased prevalence in the elderly female population [10-12].

*Role of tobacco smoking*

Smoking is a well-established risk factor in duodenal ulcer disease [13-18], even though this has long been disputed [19]. The epidemiologic evidence in favor of an increased risk is weaker in reflux esophagitis [20] and is mostly based on observations on the deleterious effects smoking exerts on the esophageal motility, such as a decrease in LESP [13, 21, 22], an impairment of esophageal clearance and promotion of duodenogastric reflux [23, 24].

Similarly smoking is an established risk factor for esophageal carcinoma, including adenocarcinoma in Barrett esophagus [25] and probably also for gastric carcinoma.

*Role of H. pylori*

There is a strong and uncontested association of *H. pylori* infection and peptic ulcer especially duodenal ulcer and to a lesser degree gastric ulcer [26, 27]. Similarly, *H. pylori* infection contributes to development of gastric cancer [28]. Nevertheless, more than 80 percent of patients infected with *H. pylori* never develop a peptic ulcer nor a gastric carcinoma, and this considerably reduces the discriminant power of *H. pylori* infection as a risk factor for organic dyspepsia. There is very little evidence suggesting any direct link between *H. pylori* infection and reflux esophagitis [10, 29]. Many patients with functional
dyspepsia are infected with *H. pylori*, but the prevalence of this infective agent is only marginally higher than in healthy controls [30].

*H. pylori* induces chronic gastritis in all subjects infested, but additional genetic and acquired risk factors, especially smoking, have long been postulated to play a facilitating role in the promotion of organic disease, especially peptic ulcer disease [26] (Figure 1).

**DISCRIMINANT VALUE OF GENETIC AND ACQUIRED RISK FACTORS FOR THE DISTINCTION BETWEEN ORGANIC AND FUNCTIONAL DYSPEPSIA**

There are only limited data from the literature available to show to what degree the above discussed risk factors can be considered as guidelines in helping the primary care physician to preselect patients at risk for organic dyspepsia [10, 31] with a reasonable confidence, and thus to help reduce unnecessary endoscopies. Since there is a considerable overlap for each factor between patients suffering from organic and functional dyspepsia, it is of particular interest to evaluate the additive discriminant power of more than one risk factor. It is the aim of this review paper to discuss the results of a study of our group, where these parameters were analyzed retrospectively [32], and to compare them with the few published prospectively sampled data.

**Studies on combined risk of *H. pylori* and smoking**

Two hundred and eighty-two patients referred from their primary care physician were enrolled into our dyspepsia study [7] if they met the following criteria: symptoms for a minimum of one month, informed consent for drug trial, including upper gastrointestinal endoscopy and *H. pylori* status (based on CLO-urease test on three biopsy samples). All were prospectively screened for criteria suggesting an organic origin of the disorder such as nocturnal pain, severe pain, severe regurgitation or heartburn, loss of weight, pain relieved by food, age of more than 50 years, *H. pylori* status and nicotine abuse. Nonparametric data were given as absolute numbers or percentages. Comparisons were made with the chi-square method (with Yates correction where necessary) and the chi-squared test for trend
Of the patients, 112/282 (39.5 percent) were *H. pylori* positive. Overall, 16 percent of patients had one or more relevant lesions: 7.8 percent esophagitis, 8.5 percent duodenal ulcers and 1.8 percent gastric ulcers. None of the above mentioned clinical criteria had an unequivocal discriminant power. However, three other factors appeared to be related to a higher prevalence of lesions in this population of dyspeptic patients. In decreasing order of discriminant power they were: a positive CLO-urease test (indicating *H. pylori* infection), smoking and male gender.

Consequently, the population—both genders individually and pooled—was stratified into four subgroups:

1. Patients who did not smoke and had a negative CLO-urease test (CLO-Nik-).
2. Patients who did smoke and had a negative CLO-urease test (CLO-Nik+).
3. Patients who did not smoke and had a positive CLO-urease test (CLO+Nik-).
4. Patients who did smoke and had a positive CLO-urease test (CLO+Nik+).
Patients with both a positive CLO-urease test and who smoked accounted for only 16 percent of the population but for 46 percent of the lesions, but lesions were seen in only four percent of the 42 percent of the subjects who were non-smokers and had a negative CLO-urease test.

The odds ratios representing the discriminant power of these acquired factors are presented in Figures 2 and 3.

Overall, and in particular for the duodenal ulcer subgroup, a negative *H. pylori* status in combination with non-smoking represented a highly significant negative discriminant factor for organic disease (odds ratio: 0.22 [0.07-0.67, 95 percent confidence interval], p < .001, and 0.13 [0.02-.93, 95 percent confidence interval], p < .001, respectively), while the reverse situation, namely a positive CLO test and smoking were reflected by a highly significant positive risk factor for organic disease (odds ratio: 4.35 [1.84-10.29, 95 percent confidence intervals], p < .001, and 5.53 [1.97-15.53, 95 percent confidence intervals], p < .001). Similarly, male sex had a high discriminant power for organic disease in the whole group (odds ratio: 3.56 [1.81-6.98, 95 percent confidence intervals], p < 0.001), as well as in the duodenal ulcer subgroup (odds ratio: 2.65 [1.12-6.28, 95 percent confidence intervals], p < .05).

In reflux esophagitis (data not shown), *H. pylori* status and smoking had a weaker discriminant power as compared to male sex. In all four groups, males had a higher prevalence for the latter disease (odds ratio corrected for smoking and *H. pylori* status: 4.54 [1.8-9.5, 95 percent, confidence intervals], p < .001) The CLO-Nik- group had a significantly lower probability of having an esophagitis (odds ratio: 0.46 [0.13-1.63, 95 percent confidence intervals], p < .05). Inversely, patients with a positive CLO-urease test and/or smoking taken as a group had a significantly higher probability of having an esophagitis than the *H. pylori*-negative non-smokers (combined odds ratio: 2.58 [1.01-7.27, 95 percent confidence intervals], p < .05).
Halter and Brignoli: H. pylori and smoking

Figure 4. Stepwise chi-square test by highest value at each step. Data for all endoscopically found relevant lesions. CLO-test indicates urease test for H. pylori infection. All X2 values represent a factor with significant discriminant power within the stepwise chi-square test. F = female, M = male, Y = yes, N = no. Data given in percent indicate the percentage of the total number of patients included in the study (n = 282).

The data were further analyzed by sequential chi-square test (an analysis that allows weighing the independent contribution of each factor analogous to a stepwise regression analysis) in which each of the putative risk factors is tested and the population stratified for the most highly significant parameter. Each subpopulation is retested for the remaining risk factors, until no significant differences remain (Figures 4 and 5). The most important risk factor for all lesions taken together and in particular for duodenal ulcer disease tested separately was a positive CLO test, followed by smoking. Male gender followed by smoking were the two dominant risk factors in the CLO-ulcer group and similarly in patients with reflux esophagitis. H. pylori infection only marginally qualified as a risk factor in patients with reflux esophagitis, particularly in female patients (p < .1).

Analysis of the data in view of endoscopic yield revealed that 1:24 endoscopies were positive in the CLO-Nik-group, 1:6 if the patients had either a positive CLO-test or were smokers, and 1:2 in patients who were in the CLO+Nik+ group. Regarded separately, the corresponding positive yields were 1:30, 1:10 and 1:7 for reflux esophagitis and 1:119 (CLO-Nik-), 1:26 (smokers), 1:13 (CLO+) and 1:3 (CLO+Nik+) for duodenal ulcers.

Gender, positive H. pylori status and smoking, thus, had an important and additive discriminant value to distinguish between organic and functional dyspepsia. The results strongly suggest that preselection of patients according to smoking habits and H. pylori status is more helpful in avoiding unnecessary endoscopies in primary care patients as compared to clinical risk factors based on patient complaints. Since this statement is based on a retrospective analysis, and since H. pylori status was assessed at endoscopy, this observation needs to be further verified by prospective studies with the use of a highly sensitive non-invasive method for H. pylori screening, ideally with the help of the $^{13}$C-urea breath test or one of the new highly specific serological tests. A prospective study partly
fulfilling these requirements has recently been published [31]. Earlier data are also available from prospective studies where *H. pylori* status was assessed by serology [10]. The latter study revealed that, a positive *H. pylori* serology fulfills together with a history of sinister symptoms the criteria of an independent risk factor, helping considerably to cut down on unnecessary endoscopies.

In the study where *H. pylori* status was prospectively assessed with the $^{13}$C urea breath test, 327 patients were referred for endoscopy [31]. Organic dyspepsia was found in 52 percent of those with a positive result. By contrast, less than 79 percent of those with a negative breath test had no abnormality at endoscopy. The stepwise logistic regression analysis identified smoking, previous upper gastrointestinal investigation and duration of symptoms as significant independent predictors of ulcer disease in the *H. pylori* positive subjects. The peptic ulcers prevalence was found to be almost two-fold as frequent in *H. pylori*-positive smokers as compared to *H. pylori*-negative smokers. Unfortunately, the data of that study are not fully comparable with those of our study. Their study was not performed on primary care patients, and the rate of relevant organic dyspepsia was considerably higher. Moreover, the *H. pylori* prevalence in their population was much higher (65 percent vs. 39 percent in our study), and the prevalence of peptic ulcers was even more unbalanced (32 percent vs. 10.3 percent in our study). No attention was given to the
question of whether reflux esophagitis is more frequent in *H. pylori*-infected smokers. Nevertheless, the data collected in a selective group confirm our findings collected among primary care patients that smoking is a prominent facilitator of organic dyspepsia in *H. pylori* positive subjects, particularly for duodenal ulcer disease.

The additive risk smoking plays in *H. pylori*-positive subjects in developing a peptic ulcer is indirectly confirmed by the observation of an Australian group that smoking is no longer a risk factor for ulcer recurrence once *H. pylori* is eradicated [33].

**POSSIBLE REASON FOR INCREASED RISK OF SMOKING IN *H. PYLORI* POSITIVE SUBJECTS**

It has been speculated that the excess of peptic ulcer disease in cigarette smokers may be explained by their increased susceptibility to *H. pylori* infection [33]. It is more likely that the mucosa of *H. pylori*-infected subjects is more susceptible to smoking-induced damage, e.g., by reducing blood flow as suggested by Taha et al. [35].

**CONCLUSION**

There is increasing evidence that smoking represents a very substantial additive risk for development of organic dyspepsia in *H. pylori*-positive subjects. This relates particularly to peptic ulcer disease, whereas its relation to reflux esophagitis needs further investigation. Similarly, male gender and advanced age are accompanied by a higher risk for organic dyspepsia. Clearly, absence of any of these risk factors does not fully exclude organic disease, but the likelihood of finding relevant pathology in young *H. pylori*-negative subjects who are non-smokers is an important argument against an early endoscopy in this group. Here, endoscopy should be reserved to those patients who do not respond to a simple probatory therapy within one to two months.

**REFERENCES**

1. Talley, J., McNeil, D., Hayden, A., Colreavy, C., and Piper, D.W. Prognosis of chronic unexplained dyspepsia. Gastroenterology. 92:1060-1066, 1987.
2. Drossman, D.A., Li, Z., Andruzzi, E., Temple, R.D., Talley, N.J., Thompson, W.G., Whitehead, W.E., Janssens, J., Funck-Jensen, P., and Corazziari, E. U.S. householder survey of functional gastrointestinal disorders—prevalence, sociodemography, and health impact. Dig. Dis. Sci. 38:1569-1580, 1993.
3. Brignoli, R., Merki, H. Miazza, B., and Beglinger, C. Endoskopische Befunde bei freiwilligen und dyspeptischen Patienten. Schweiz Med Wochenschr. 124:1240-1247, 1994.
4. Mansi, C., Mela, G.S., Pasini, D., Grosso, M., Corti, L., Moretti, M., and Celle, G. Patterns of dyspepsia in patients with no clinical evidence of organic diseases. Dig. Dis. Sci. 35:1452-1458, 1990.
5. Johannessen, T., Petersen, H., Kleveland, P.M., Dybdahl, J.H., Sandvik, A.K., Brenna, E., and Waldum, H. The predictive value of history in dyspepsia. Scand. J. Gastroenterol. 25:689-97, 1990.
6. Knill-Jones, R.P. Geographical differences in the prevalence of dyspepsia. Scand. J. Gastroenterol 26(suppl 182):17-24, 1991.
7. Brignoli, R., Watkins, P., and Halter, F. The Omega-Project—a comparison of two diagnostic strategies for risk- and cost-oriented management of dyspepsia. Eur. J. Gastroenterol. Hepatol. 9:337-343, 1997.
8. Halter, F. Dyspepsia and *Helicobacter pylori*: to endoscope or not to endoscope? (letter). Gastroenterology 111:1159, 1996.
9. Talley, N.J., McNeil, D., and Piper, D.W. Discriminant value of dyspeptic symptoms: a study of the clinical presentation of 221 patients with dyspepsia of unknown cause, peptic ulceration, and cholelithiasis. Gut 28:40-61, 1987.
10. Patel, P., Khulusi, S., Mendall, M.A. Lloyd, R., Jazrawi, R., Maxwell, J.D., and Northfield, T.L. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet. 346:1315-8, 1995.

11. Sonnenberg, A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects Am. J. Gastroenterol. 91:1773-1777, 1996.

12. Schubert, T.T., Bologna, S.D., Nensey, Y., Schubert, A.B., and Mascha, E.J. Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age. Am. J Med. 94:13-18, 1993.

13. Sontag, S.J., Schnell, T.G., Miller, T.Q., Nemchavsky, B., Serlovsky, R., O’Connell, S., Chejfec, G., Seidel, W., and Brand, L. The importance of hiatal hernia in reflux esophagitis compared with lower esophageal sphincter pressure or smoking. J. Clin. Gastroenterol.13:628-43, 1991.

14. Pelissero, A. and Sategna-Guidetti, C. Epidemiologic aspects of peptic ulcer disease in Northern Italy. J. Clin. Gastroenterol. 11:351-356, 1989.

15. Friedman, G.D., Siegelaub, A.G., and Seltzer, C.C. Cigarettes, alcohol and peptic ulcer N. Engl. J. Med. 290:469-473, 1974.

16. Gillies, M.A. and Skyring, A. Gastric and duodenal ulcer: the association between aspirin ingestion, smoking and family history of ulcer. Med. J. Aust. 2:280-285, 1969.

17. Klaus, A.G. and Moller-Lissner, S.A. Rauchen und gastrointestinal funktion. Z. Gastroenterol 31:486-492, 1993.

18. Parente, F., Lazzaroni, M., Sangaletti, O., Baroni, S., and Bianchi Porro, G. Cigarette smoking, gastric acid secretion, and serum pepsinogen 1 concentrations in duodenal ulcer patients. Gut 26:1327-1322, 1985.

19. Wormsley, K.G. Smoking and duodenal ulcer. Gastroenterology 75:139-142, 1978.

20. Schindelbeck, N.E., Klaus, A.G., Berghammer, G., Londong, W., and Muller-Lissner, S.A. Three year follow up of patients with gastroesophageal reflux disease. Gut. 33:1016-1019, 1992.

21. Dennish, G.W. and Castell, D.O. Inhibitory effect of smoking on the lower esophageal sphincter. N. Engl. J. Med. 284:1136-1137, 1971.

22. Chattopadhyay, D.K., Greaney, M.G., and Irving, T.T. Effect of cigarette smoking on the lower esophageal sphincter. Gut. 18:833-835, 1977.

23. Mittal, R.K., Lange, R.C., and McCallum, R.W. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia Gastroenterology. 92:130-135, 1987.

24. Kjellin, G. and Tibbling, L. Influence of body position, dry and water swallows, smoking, and alcohol on esophageal acid clearing. Scand. J. Gastroenterol. 13:283-8, 1978.

25. Gray, M.R., Donnelly, R.J., and Kingsnorth, A.N. The role of smoking and alcohol in metaplasia and cancer risk in Barrett’s columnar lined oesophagus Gut 34:727-731, 1993.

26. Graham, D.Y., Colon-Pagan, J., Morse, R.S., Johnson, T.L., Walsh, J.H., McCullough, A.J., Marks, J.W. Sklar, M., and Stone, R.C. Ulcer recurrence following duodenal ulcer healing with omeprazol, ranitidine, or placebo. A double-blind, multicenter, 6-month study. Gastroenterology 102:1298-1294, 1992.

27. Halter, F. and Zetterman, RK. Long-term effects on HP infection on acid and pepsin secretion Yale J. Biol. Med. 69:99-104, 1996.

28. Forman, D. Helicobacter pylori and gastric cancer. Scand. J. Gastroenterol. 31(suppl 220):232-6, 1996.

29. Werdmuller, B.F.M. and Loffeld, R.J.L.F. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig. Dis. Sci. 42:103-105, 1997.

30. Řokkas, T., Pursey, C., Uzoechina, E., Dorrington, L., Simmons, N.A., Filipe, M.I., and Sladen, G.E. Campylobacter pylori and non-ulcer dyspepsia Am. J. Gastroenterol. 82:1149-52, 1987.

31. McColl, K.E.L., El-Nujumi, A., Murray, L., el-Ómar, E., Gillen, D., Dickson, A., Kelman, A., and Hilditch, T.E. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients Gut 40:302-306, 1997.

32. Halter, F. and Brignoli, R. Epidemiology of dyspepsia: discriminant values of smoking and Helicobacter status as predictors of peptic lesions in primary care. J. Physiol. Pharmacol. 48(suppl 4):75-83, 1997.

33. Borody, T.J., George, L.E., Brandl, S.A., Andrews, P., Jankiewicz, E., and Ostapowicz, N. Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. Am. J. Gastroenterol. 87:1390-1393, 1992.

34. Bateson M.C. Cigarette smoking and Helicobacter pylori infection. Postgrad. Med. J. 69:41-44, 1993.

35. Taha, A.S., Angerson, W., Nakshabendi, L., Beekman, H., Morran, C., Sturrock, R.D., and Russell, R.I. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs: influence of age, smoking, ulceration and Helicobacter pylori. Aliment. Pharmacol. Ther. 7:41-45, 1993.